Status:

COMPLETED

BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy

Lead Sponsor:

Braintree Laboratories

Conditions:

Colon Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This is a randomized, parallel, multi-center, single-blind study, comparing BLI850 to an FDA approved bowel preparation in adult subjects undergoing colonoscopy.

Eligibility Criteria

Inclusion

  • Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication, including:
  • Evaluation of barium enema results
  • GI bleeding
  • Anemia of unknown etiology
  • Neoplastic disease surveillance
  • Abnormal Endosonography
  • Inflammatory bowel disease
  • Unknown diarrhea or constipation etiology
  • Polypectomy
  • Laser therapy
  • Routine screening
  • At least 18 years of age.
  • Otherwise in good health, as determined by physical exam and medical history.
  • If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, intra-uterine device, double-barrier method, depot contraceptive, abstinent, or vasectomized spouse).
  • Negative urine pregnancy test at screening, if applicable.
  • In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study.

Exclusion

  • Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon.
  • Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
  • Subjects who are undergoing colonoscopy for foreign body removal or decompression.
  • Subjects with clinically significant electrolyte abnormalities based on Visit 1 laboratory results.
  • Subjects who had previous significant gastrointestinal surgeries (e.g. colostomy, colectomy, gastric bypass).
  • Subjects who are pregnant or lactating, or intending to become pregnant during the study.
  • Subjects of childbearing potential who refuse a pregnancy test.
  • Subjects who are allergic to any preparation components
  • Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.
  • Subjects who have participated in an investigational surgical, drug, or device study within the past 30 days.

Key Trial Info

Start Date :

August 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

386 Patients enrolled

Trial Details

Trial ID

NCT00756548

Start Date

August 1 2008

Last Update

December 27 2013

Active Locations (12)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (12 locations)

1

Advanced Clinical Research Institute

Anaheim, California, United States, 92801

2

Advanced Clinical Research Institute

Orange, California, United States, 92869

3

Indiana University Medical Center

Indianapolis, Indiana, United States, 46202

4

Gastrointestinal Associates

Jackson, Mississippi, United States, 39202